Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Emerging Subspecialties in Neurology: Neuroimmunology
Neurol 79:e178-e180, Clardy, S., 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Should we be nervous about coeliac disease? Brain abnormalities in patients with coeliac disease referred for neurologic opinion
JNNP 83:1216-1221, Currie, S.,et al, 2012
Distinct Lesion Morphology at 7-T MRI Differentiates Neuromyelitis Optica from Multiple Sclerosis
Neurol 79:708-714, Sinnecker, T.,et al, 2012
Painful Tonic Spasm in Neuromyelitis Optica
Arch Neurol 69:1026-1031, Kim, S.M.,et al, 2012
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis
Arch Neurol 69:1259-1269, Radue, E.W.,et al, 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012
Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012
Recovery after Spinal Cord Infarcts
Neurol 78:114-121, Robertson,C.E.,et al, 2012
Assessing Abnormal Iron Content in the Deep Gray Matter of Patients with Multiple Sclerosis verus Healthy Controls
AJNR 33:252258, Habib,C.A.,et al, 2012
Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012
Solitary Sclerosis
Neurol 78:540-544, Schmalstieg,W.F.,et al, 2012
Fingolimod-Associated Macular Edema
Neurol 78:672-680, Jain,N. and Bhatti,M.T., 2012
Serologic Diagnosis of NMO
Neurol 78:665-671, Waters,P.J.,et al, 2012
Neuromyelitis Optica and Pregnancy
Neurol 78:875-879, Bourre,B.,et al, 2012
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
NEJM 366:1000-1009, Comi,G.,et al, 2012
Diffusion-weighted imaging characteristics of biopsy-proven demyelinating brain lesions
Neurol 78:1655-1662, Abou Zeid, N.,et al, 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
"Undiagnosing" Multiple Sclerosis
Neurol 78:1986-1991,1904, Solomon, A.J.,et al, 2012
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Inflammatory Cortical Demyelination in Early Sclerosis
NEJM 365:2188-2197, Lucchinetti, C.F.,et al, 2011
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Syndrome of Inappropriate Antidiuresis May Herald or Accompany Neuromyelitis Optica
Neurol 77:1644-1645, Iorio, R.,et al, 2011
Hypereosinophilia in Patients with Multiple Sclerosis Treated with Natalizumab
Neurol 77:1561-1564, Abbas, M.,et al, 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
N-methyl-D-aspartate Receptor Autoimmune Encephalitis Presenting With Opsoclonus-Myoclonus
Arch Neurol 68:1069-1072, Smith, J.H.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Drug-Resistant Epilepsy
NEJM 365:919-26, Kwan, P.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Yellow Fever Vaccination and Increased Relapse Rate in Travelers with Multiple Sclerosis
Arch Neurol 68:1267-1271, Farez, M.F. and Correale, J., 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
Acute Myeloid Leukemia in Italian Patients with Multiple Sclerosis Treated with Mitoxantrone
Neurol 77:1887-1895, Martinelli, V.,et al, 2011
Multiple Sclerosis-Quenching the Flames of Inflammation
Lancet 378:1759-1760, , 2011
A Strange Case of Waitress Headache
Lancet 378:1824, Libera, D.D.,et al, 2011
MRI Only Conversion to Multiple Sclerosis Following a Clinically Isolated Syndrome
JNNP 82:176-179, Chard,D.T.,et al, 2011
CSF Complements Serum for Evaluating Paraneoplastic Antibodies and NMO-IgG
Neurol 76:1108-1110, McKeon,A.,et al, 2011
A Clinical Prediction Rule for Ambulation Outcomes After Traumatic Spinal Cord Injury: A Longitudinal Cohort Study
Lancet 377:1004-1010, 972, van Middendorp,J.J,et al, 2011
Asymptomatic Spinal Cord Lesions Predict Disease Progression in Radiologically Isolated Syndrome
Neurol 76:686-692, 680, Okuda,D.T.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Ann Neurol 69:75-82, Comi,G.,et al, 2011
When A Brain Lesion Necessitates Chest CT
Conn Med 75:143-146, Finelli,P.F., 2011
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Ann Neurol 69:292-302, 234, Polman,C.H.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011